This episode of Drug Digest will discuss where the significant bottlenecks are in the development and manufacturing of new ...

Under the partnership, Pharmaron will validate and promote the application of CN Bio’s PhysioMimix technology and will integrate OOC technologies into its R&D platform.

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Eric Schmidt’s AI predictions reveal a future of innovation, risks, and ethical dilemmas. Are we ready for the rise of ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

TAL61 demonstrated significant anti-tumor properties with strong tolerability in patient-derived xenograft models of chordoma TAL61 showed robust single-agent activity in Brachyury-positive non-small ...

Insmed invests heavily in a robust pipeline with multi-billion potential, positioning for future growth. Check out why INSM ...

OP-3136 showed activity that was independent of KAT6 amplification or over expression. In the OVCAR3 model, OP-3136 monotherapy demonstrated sustained tumor regression across the 28-day study period ...

Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

America’s position as the world’s dominant nation began after World War II with the appreciation that science played an outsized role in winning the war. For that reason, the US decided that the ...

According to the press release issued by the New York State Police, everything began when members of the Troop K Community ...

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...